Physician profile
Katie E Luigs
NPI 1487080529
$4,769.86
in general payments reported to CMS, 2019-2025
28 companies · $628 in 2025
The $628 reported for 2025 was more than what 80% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,013 · 2022: $1,102 · 2023: $1,392 · 2024: $634 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,654.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,470.53 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $466.88 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Celgene Corporation | $466.77 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $315.92 | 2022-2025 | Stelara, Simponi, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $228.43 | 2021-2025 | Entyvio |
| Gilead Sciences, INC. | $203.27 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $197.21 | 2022-2025 | Dupixent |
| Genzyme Corporation | $160.75 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $140.43 | 2021 | |
| Intercept Pharmaceuticals, INC. | $138.39 | 2021-2025 | Ocaliva |
| Amgen INC. | $115.57 | 2021-2023 | Avsola, Amjevita |
| Pfizer INC. | $104.79 | 2022-2024 | |
| Organon LLC | $103.93 | 2023-2025 | Renflexis, Hadlima |
| Ardelyx, INC. | $94.60 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $89.19 | 2023-2024 | Linzess |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $68.88 | 2025 | Rezdiffra |
| Qol Medical, LLC | $67.63 | 2022-2025 | Sucraid |
| Braintree Laboratories, INC. | $57.96 | 2022-2025 | Suflave |
| Phathom Pharmaceuticals, INC. | $53.53 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $45.90 | 2023 | Stelara |
| Aimmune Therapeutics, INC. | $31.47 | 2024 | |
| Merck Sharp & Dohme LLC | $28.04 | 2021-2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $26.61 | 2023 | |
| Fresenius Kabi USA, LLC | $24.02 | 2024 | Idacio |
| Ferring Pharmaceuticals INC. | $20.91 | 2023 | Rebyota |
| Lilly USA, LLC | $17.99 | 2024 | Omvoh |
| Mauna Kea Technologies, INC. | $16.94 | 2024 | |
| Amag Pharmaceuticals, INC. | $13.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Luigs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.